Gattefossé is strengthening its global footprint with the grand opening of its first production facility in North America. Having established a presence in the United States in 1982 with a sales office in Paramus, New Jersey, and later expanded with the launch of its Technical Center of Excellence in 2017, the company is now taking a decisive step in deepening its presence on the continent.
The Lufkin plant, dedicated to lipid-based excipients, was designed with a dual objective: to expand production capacity and to strengthen Gattefossé’s presence in a market that is strategic for the group in both pharmaceuticals and personal care. This new facility marks Gattefossé’s largest investment since the company’s founding in 1880. Lufkin, in East Texas, sits at the crossroads of Dallas, Houston, and Shreveport, making it a strategic logistics hub.
A transformative investment
Designed as a long-term commitment to Gattefossé’s North American customers, the new production site boosts capacity, secures supply chains, and shortens lead times — all while upholding the same high-quality standards as the group’s other production sites across the globe.
In March 2025, the Lufkin plant was awarded three world-class certifications - ISO 9001, EFfCI GMP, and EXCiPACT - recognizing Gattefossé’s rigorous approach to quality, safety, and compliance in both pharmaceutical and cosmetic ingredient manufacturing. In addition to efficiency and performance, the site was designed according to LEED certification criteria, ensuring it meets the highest environmental standards.
With this new site, alongside its historic Saint-Priest factory in France and the Singapore facility launched in 2012, Gattefossé now spans three continents. Through this global industrial network, Gattefossé aims to enhance supply chain resilience and bring itself closer to its customers.
“The opening of our new plant in Lufkin marks a major milestone in our company’s journey. Choosing the United States was a strategic decision: this region is not only a leading market but also a global trendsetter in pharmaceuticals and personal care. This plant is more than a building; it is a promise to grow, to innovate, and to create value together with confidence, responsibility, and passion,” said Ségolène Moyrand-Gros, President of Gattefossé Group.
The inauguration ceremony gathered local and national officials, including Congressman Pete Sessions and Mayor Mark Hicks, alongside Gattefossé executives, customers, partners, employees, and community members.
“Our partnership with Gattefossé is rooted in history, shaped by science, and built on trust. This new U.S.-based footprint is more than an operational expansion, it’s a powerful lever for performance. By locating closer to our development sites and manufacturing hubs, Gattefossé reduces supply risk, strengthens resilience, and ensures real-time collaboration. In our fast-moving world, proximity isn’t a convenience, it’s a competitive advantage. This investment tells the world that Gattefossé is scaling with purpose and strengthening the reliability and quality of the entire supply chain,” emphasized Diana Trepanier, Vice President Procurement, Pharma & Consumer Health at Catalent, on this occasion.
A specialist in lipid chemistry and plant extraction for the personal care and pharmaceutical industries, Gattefossé had launched this USD 50 million investment in 2022.
